



- Six companies are working on the LPV/r formulation, of which:
 - Three MPP licensees approved: **Aurobindo, Hetero** and **Mylan**
 - Two additional companies (non-licensees) approved: **Cipla** and **Macleods**
 - An additional licensee is planning to file in 1st half of 2019
- Currently approved in 40 countries and filed in another 10 countries
 - Total filing coverage: 95.3% of PLHIV in LMICs